Corporate Banner
Satellite Banner
Informatics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Novozymes and Syngenta to partner in delivering JumpStart® — For enhanced phosphate fertility within bioagriculture

Published: Friday, May 11, 2012
Last Updated: Friday, May 11, 2012
Bookmark and Share
The agreement provides an exclusive expansion into new markets for JumpStart, which is a biological that enhances phosphate fertility in agriculture, offering growers an integrated and sustainable seed care solution

 Novozymes and Syngenta today announced a global agreement under which Syngenta will work with Novozymes to commercialize JumpStart technology, a seed-applied biological that increases phosphate solubilization in the soil. The two companies will jointly develop the market for JumpStart in combination with Syngenta’s Seed Care portfolio on arable crops, including cereals and corn. The agreement extends the geographical potential of JumpStart, currently sold mainly in North America, to the rest of the world.

Thomas Videbaek, Executive Vice President, Novozymes, comments: “Partnering with Syngenta supports Novozymes’ strategic goal to provide the world with natural and biological solutions to help farmers worldwide increase their yields to feed the world's growing population.”

Phosphorus is an essential macronutrient for the healthy growth of young plants.  JumpStart is based on a unique fungus, Penicillium bilaii, which increases phosphate solubilization for uptake into the plant through the root system. The market potential for seed-applied technologies that increase phosphate use efficiency is estimated at over $100 million.

John Atkin, COO Syngenta, says: “We're pleased to enter into this agreement with Novozymes, which marks a further addition to our growing range of bioactives. Our Seed Care portfolio already offers best-in-class control of insects and diseases together with crop enhancement benefits. With the addition of JumpStart, growers will now gain the added advantage of improved phosphate efficiency.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Shengquan and Novozymes in partnership to commercialize cellulosic ethanol
The Chinese Shengquan Group will start commercial production of cellulosic ethanol for solvents and biochemicals in June 2012 utilizing enabling technology from Novozymes
Friday, May 11, 2012
Novozymes Announces Master File for Recombinant Albumin
The dossier, containing information on the manufacture and safety of albucult, can help support the medical devices and drug formulation applications.
Friday, September 03, 2010
Scientific News
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Connectome Map More Than Doubles Human Cortex’s Known Regions
Researchers at NIH have developed software that automatically detects the “fingerprint” of each of these areas in an individual’s brain scans.
Virus Inspired Cell Cargo Ships
Virus-inspired container design may lead to cell cargo ships following construction of ten large, two-component, icosahedral protein complexes.
Three-Drug Combinations Counter Antibiotic Resistance
Research shows that combinations of three different antibiotics can treat resistant bacteria, even if they are ineffective independently.
Supercomputing and Drug Discovery
New biotech company uses supercomputer simulations to speed up drug discovery and biotech molecule development.
Identifying Cancer Drug Targets Using 3D-Modelling
Researchers are now able to model genetic mutations manipulation of proteins that can potentially drive cancer.
Human Evolution Driven by Viruses
Study finds surprising percentage of protein adaptions in humans have been driven by viruses.
Earliest Sign of Alzheimer's Development Discovered
Researchers have identified the first physiological signs of late-onset Alzheimer's disease, underlining the importance of computational power in neurology.
Computational Method Offers Significant Boost in Finding New Cancer Targets
MIT and ARIAD Pharmaceuticals team have identified evidence of significant cancer mutations.
Drug Response Predicted by Cancer Cell Lines
Large-scale study could increase success rate of developing personalised cancer treatments.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!